Autoimmune Chronic Pancreatitis  by Lin, Lien-Fu et al.
J Chin Med Assoc • January 2008 • Vol 71 • No 114
© 2008 Elsevier. All rights reserved.
*Correspondence to: Dr Lien-Fu Lin, Division of Gastroenterology, Department of Internal Medicine, Tung’s Taichung
Metroharbor Hospital, No. 8, 11th Floor, Mei Tsun Road, Section 2, Lane 168, Taichung 402, Taiwan, R.O.C.
E-mail: aucardla@yahoo.com.tw ● Received: July 16, 2007 ● Accepted: December 31, 2007
Introduction
Sarles et al first described a form of chronic pancreati-
tis with marked swelling, lymphocyte infiltration and
hypergammaglobulinemia in 1961.1 Autoimmune
pancreatitis (AIP) was then introduced by Yoshida and
co-workers in 1995.2 AIP is defined as a form of chronic
pancreatitis caused by autoimmune inflammatory
process with heavy lymphocyte infiltration and fibro-
sis that result in organ dysfunction.3 There are various
morphologic descriptions to characterize this disease:
nonalcoholic duct-destructive chronic pancreatitis,4
lymphoplasmacytic sclerosing pancreatitis with cholan-
gitis,5 chronic sclerosing pancreatitis,6 pseudotumorous
pancreatitis,7 and duct-narrowing chronic pancreati-
tis;8 AIP is now widely accepted. AIP can present with
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Background: Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis that is characterized by swelling of
the pancreas, narrowing of the main pancreatic duct (MPD), elevation of serum gamma globulin, or immunoglobulin G or
presence of autoantibody, lymphoplasmacytic infiltration and dense fibrosis on histopathology. It is responsive to steroid
therapy. The incidence of AIP can reach 5–6% of chronic pancreatitis. It can present as obstructive jaundice, body weight
loss, and pancreas head mass mimicking pancreatic cancer. The recognition of AIP can avoid major surgery such as 
pancreatic resection.
Methods: From May 2003 to July 2007, a total of 5 cases of AIP were reviewed retrospectively. The diagnosis was made
on imaging study, serology, steroid response and/or histology if surgery was carried out.
Results: There were 2 male and 3 female patients, with a mean age of 61 (39–75) years. Atypical AIP was found in the first
case and typical AIP in the remaining 4. The presenting clinical pictures were mild epigastric pain, obstructive jaundice,
and loss of body weight in 4 cases, with associated autoimmune disease in 1. Diffuse or long segmental enlargement of
the pancreas without peripancreatic fat infiltration was found in all patients except 1 who only had focal pancreatic head
enlargement. Distal common bile duct (CBD) stricture was seen in 4 cases and the median CBD stricture length was 
1.2 (0.5–2.5) cm. Multiple narrowing of the whole MPD was seen in 2 cases, focal narrowing of the MPD in 2 and long
segmental narrowing of the MPD in 1. Serum immunoglobulin G tests were done in 4 cases and were elevated in all.
Antinuclear antibody was positive in 3. The first case was operated on after a preoperative diagnosis of suspicious 
pancreatic head tumor. The subsequent 3 cases were diagnosed correctly as AIP. The last case presented with distal
CBD stricture and hypoechoic lesion in the pancreas head on endoscopic ultrasound, with only borderline pancreatic
enlargement on computed tomography, and he was operated on. Retrospective endoscopic retrograde pancreatogram
review revealed MPD narrowing in the pancreatic body. Endoscopic retrograde brush cytology was performed and was
negative for malignancy in 3 cases. Steroid therapy was given in 3 and was responsive, but there were 2 recurrences.
Conclusion: AIP should be a differential diagnosis in distal CBD stricture and pancreatic head mass when the patient has:
(1) diffuse or long segmental enlargement of the pancreas without peripancreatic fat infiltration, with multiple narrowing
of the MPD without much upstream dilatation, or narrowing of the MPD not corresponding to the region of CBD stricture;
and (2) abnormal immunoserologic tests. [J Chin Med Assoc 2008;71(1):14–22]
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pancreas-related symptoms such as mild epigastric pain,
loss of body weight, obstructive jaundice,9 and extra-
pancreatic symptoms such as associated autoimmune
diseases like Sjögren’s syndrome, rheumatoid arthri-
tis, inflammatory bowel disease, and retroperitoneal
fibrosis.10–15 It can present as an atypical form of AIP
with focal pancreatic mass mistaken as pancreatic can-
cer.16–18 One quarter of Whipple resection (benign
cases) was due to AIP in North America,19 so by rec-
ognizing the disease, major surgery can be avoided.
Herein, we report our experience with 5 cases of AIP.
Methods
From May 2003 to July 2007, a total of 5 cases of
AIP (with no alcohol history) were reviewed retro-
spectively. The diagnosis was made on imaging study
and one of the following criteria: serology, steroid
response and histology if surgery was carried out.20,21
Computed tomography (CT), endoscopic retrograde
cholangiopancreatography (ERCP), and serology for
antinuclear antibody (ANA) were performed in all 
5 cases. Serum immunoglobulin (Ig) G was measured
in 4 cases, endoscopic retrograde brush cytology
(ERBC) in 3, and endoscopic transpapillary biopsy
(ETPB) from distal common bile duct (CBD) in 2.
Enlarged pancreas was considered if the anteroposte-
rior diameter of the pancreas was greater than 2 cm
on CT.22
Results
There were 2 male and 3 female patients, with a mean
age of 61 (39–75) years. The clinical pictures, associ-
ated autoimmune disease, image pattern of the pan-
creas, main pancreatic duct (MPD), length of distal
CBD stricture, serology results, steroid outcome, and
follow-up duration are shown in Table 1.
In the first case (Figure 1), total bilirubin was
6.6 mg/dL, carcinoembryonic antigen (CEA) was
2.8 ng/L (upper limit, 5 ng/L), CA19-9 was 109 U/
mL (upper limit, 33 U/mL), and ANA was positive 
at 1:320. She was operated on after a preoperative
diagnosis of suspicious pancreatic uncinate process
tumor, distal CBD stricture, obstructive jaundice and
with a biliary stent in situ. Intraoperative biopsy showed
fibrosis, lymphocyte infiltration, small pancreatic duct
destruction and obliterative phlebitis (Figure 2), and
pancreas resection was not performed. She was given
steroid therapy (prednisolone 40 mg/day for 1 week,
followed by 5 mg reduction/week). The MPD and Ta
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CBD stricture resolved after 8 weeks (by ERCP), and
she then maintained good response for 4 years.
The subsequent 3 cases were diagnosed as AIP
without operation. The second case (with distal CBD
stricture and obstructive jaundice; Figure 3) had total
bilirubin of 2.9 mg/dL, CEA of 2.9 ng/L, CA19-9
of 83.8 U/mL, and negative ANA. He was given
steroid therapy (same dose as Case 1) but the clinical
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Figure 1. (A) Computed tomography shows a focal mass in the pancreas head region (arrow). (B) ERC shows distal stricture (arrow). (C) ERP
reveals multiple narrowing of the main pancreatic duct (arrows). (D) Resolved main pancreatic duct narrowing after steroid therapy.
BA
Figure 2. (A) Histology shows fibrosis (arrow). (B) Obliterative phlebitis (arrow).
course was complicated by Candida esophagitis in
the 3rd week of steroid therapy, resulting in reduced
steroid dosage (20 mg/day from the 4th week, with a
reduction of 7.5 mg/week). The distal CBD stricture
resolved after 8 weeks of steroid therapy but recurred
5 months later. Given his associated comorbid dis-
eases (ischemic heart disease, diabetes mellitus), risk
of fluid retention with higher dose of steroid, and
reluctance to undergo repeated endoscopic proce-
dure, he underwent biliary metallic stent insertion.
He was stable for 2 years until he died of intracranial
hemorrhage due to head injury.
The third case (Figure 4) had narrowing of the
MPD in the body and tail regions, without CBD
stricture. ANA was positive with a titer of 1:160, and
Sjögren’s syndrome was diagnosed in our rheumatol-
ogy department. Her CEA was 1 ng/L and CA19-9
was 4.2 U/mL. No steroid was given, and the process
remained stable for 3.5 years.
The fourth case, with typical imaging pictures
(swelling of pancreas without peripancreatic fat infil-
tration and narrowing of the MPD), presented with
ANA positive at 1:160, CEA of 4.2 ng/L, and CA19-9
of 2.5 U/mL. She had steroid therapy (prednisolone
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Figure 3. (A) Diffuse enlargement of the pancreas (arrow). (B) Distal 
common bile duct stricture (arrow). (C) Resolved distal common bile duct
stricture (arrow) after steroid therapy. (D) Multiple narrowing of the main
pancreatic duct (arrows). (E) Resolved narrowing of the main pancreatic
duct (arrows) after steroid therapy.
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Figure 4. (A) Swelling of the pancreas (arrow). (B) Irregular narrowing of the main pancreatic duct in the body and tail regions (arrows).
A B
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Figure 5. (A) Long segment enlargement of the pancreas (arrow). (B) Distal common bile duct stricture (arrow). (C) Focal narrowing of
the main pancreatic duct (arrow). (D) Endoscopic ultrasound reveals a hypoechoic mass in the pancreatic head region (arrow).
30 mg/day due to small body weight, with a reduc-
tion of 5 mg/week) with improved CBD obstruc-
tion, but recurrence of CBD stricture (by abdominal
ultrasound) and elevation of liver function test were
seen after 3 months.
The last case (Figure 5) presented with distal CBD
stricture for 2 months with borderline pancreas
enlargement on CT. Endoscopic ultrasound (EUS)
demonstrated a hypoechoic lesion in the pancreatic
head region, endoscopic retrograde pancreatogram
(ERP) revealed normal MPD in the head region. The
patient was operated on under the impression of sus-
picious intrapancreatic CBD tumor. The CEA level
was 1.6 ng/L, CA19-9 was 42.3 U/mL, and ANA
was negative. Histology showed lymphoplasmacytic
infiltration, fibrosis without fat necrosis, ductal dilata-
tion, and stone (Figure 6). Retrospective review of
ERP of the last case showed that he had focal narrow-
ing of the MPD at the body region.
ERBC was performed in 3 cases; all were negative
for malignancy. The median follow-up duration was
24 (2–48) months. Cases 2, 4 and 5 had diabetes
mellitus, but no other symptoms such as steatorrhea.
Discussion
There are 4 types of diagnostic criteria for AIP: the
revised Japanese and Kim et al’s criteria9,21 emphasize
imaging study, whereas the Mayo Clinic’s HISORt
criteria (histology, imaging, serology, other organ
involvement, and its response to steroid therapy) and
Italian criteria23,24 focus on histology. In HISORt and
the revised Japanese criteria,21,23 atypical form or
focal type of AIP or tumefactive pancreatitis are
included.25–28 The diagnoses of our cases fit with the
revised Japanese and Kim et al’s criteria9,21 in imaging
study of pancreatic enlargement (either diffuse or
focal), MPD narrowing (focal or multiple) and any one
of the following such as serology or pathology or
response to steroid. There is no international consen-
sus with regard to the diagnostic criteria for AIP. For
practical purposes, the revised Japanese and Kim et al’s
criteria would be more useful as they focus on imag-
ing studies. The revised Japanese criteria added focal
enlargement of the pancreas, and steroid response was
included in Kim et al’s criteria.
We had 2 male and 3 female patients with a mean
age of 61 years. In the literature, males are twice as
common as females, and they are usually more than
50 years old.9 Our female predominance may be due
to the small number of cases. Obstructive jaundice and
mild abdominal pain were found in 4 of 5 cases in our
series, while jaundice was seen in 63% and abdominal
pain in 35% from Kim et al’s cases.9 We had 1 case
associated with Sjögren’s syndrome. The incidence
J Chin Med Assoc • January 2008 • Vol 71 • No 1 19
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Figure 6. (A) Gross specimen: the white area corresponds to the hypoechoic
mass seen on endoscopic ultrasound (arrow). (B) Hematoxylin and eosin
staining (400×) reveals fibrosis, plasma cells and eosinophils (arrows). 
(C) Masson staining (200×) shows fibrosis (arrow).
and types of associated autoimmune disease vary with
different studies, ranging from 20% in Kim’s group
up to 50% in an Italian study.9,24 In the Italian study,
about half of the associated autoimmune disease was
diagnosed before the onset of AIP, while the remain-
ing half was diagnosed during the follow-up period.1
The most common associated autoimmune diseases
were inflammatory bowel disease in Western litera-
ture,24 rheumatoid arthritis and sialoadenitis in the
Japanese study, and retroperitoneal fibrosis in Kim et al’s
series.29
The CT images in AIP include diffuse or focal
enlargement of the pancreas with delayed homoge-
neous enhancement of focal mass or capsule like low-
density ring. The pancreatogram pictures were of
diffuse or focal narrowing of the MPD without much
upstream dilatation.30,31 We had diffuse pancreatic
enlargement in 2 cases, long segment enlargement in
2 and focal pancreatic enlargement in 1; we did not
have the delayed homogeneous enhanced parenchyma
or ring picture as mentioned in the literature.30,31 We
had diffuse narrowing of the MPD in 2 cases, long
segment narrowing of the MPD in 1 and focal nar-
rowing of the MPD in 2 without much upstream
dilatation. In the fifth case, EUS detected a hypoe-
choic mass in the pancreatic head region but with no
MPD stricture in that region; the patient was diag-
nosed with intrapancreatic CBD tumor and was oper-
ated on. Retrospectively, he did have MPD narrowing
in the body region and elevated IgG, and together
with the pathology results, he was finally diagnosed
with AIP.
With EUS, hypoechoic mass could be found in 6
of 14 cases.17 Serum IgG4 was included in Kim et al’s,
HISTORt’s, and the revised Japanese criteria for the
diagnosis of AIP. IgG4 is more sensitive than IgG in
AIP patients (73.3% vs. 54.3%), and was elevated in
20% of AIP patients without IgG elevation in Kim 
et al’s experience.9 Kawa and Hamano reported that
the sensitivity of IgG was 70.5% and that of IgG4 was
90.9% in AIP.32 In the literature, the sensitivity of
IgG4 can range from 67% to 71%.33,34 Elevated IgG4
is associated with more extrapancreatic organ involve-
ment.34 Autoantibody test was positive in 2 of 31 AIP
patients who had no elevation of IgG or IgG4,29 and
was included in Kim et al’s and the Japanese criteria.
On histology, our first and fifth cases had lympho-
plasmacytic infiltration and fibrosis which were
included in the Japanese and Kim et al’s criteria. Such
histologic findings were not specific to AIP and could
also be found in 88% of alcoholic chronic pancreati-
tis.35 The severity of lymphoplasmacytic infiltration
was dependent on the activity and stage of the disease
and could be minimal in 1 third of AIP patients.36
Lymphoplasmacytic sclerosing pancreatitis (LPSP)
and more than 10 positive IgG4 cells per high power
field can be the sole diagnostic criterion for AIP in the
HISTORt (Mayo Clinic) criteria.23 LPSP is character-
ized by dense periductal infiltration of lymphocytes,
plasma cells, perilobular, intralobular fibrosis, obliter-
ative phlebitis and a lack of the changes seen in other
chronic pancreatitis such as ductal dilatation, stones,
and fat necrosis. But these findings need a larger tis-
sue specimen, at least more than a wedge biopsy,37
and therefore has less clinical practicality. Only 8 of
14 AIP patients who underwent EUS-guided trucut
biopsy had the pictures of dense lymphoplasmacytic
infiltration and positive IgG4 stained cells of more
than 10 cells per high power field.38 Also, the diagno-
sis of LPSP required a skilled pathologist, and only 
6 of 31 cases of LPSP were correctly diagnosed the
first time round,37 and obliterative phlebitis could 
be easily missed unless elastic special stain is used.
Regarding positive IgG4 cells on histology, only 37%
of AIP patients had such findings, and they could also
be found in 25% of alcoholic chronic pancreatitis.39
In cases without preoperative suspicion of AIP, the
diagnosis of AIP can still be possible by solely
depending on histology using the HISTORt (Mayo
Clinic) criteria.
Steroid was given in 3 cases with 2 recurrences in
our series. Our third case had only narrowing of the
MPD in body and tail with no CBD stricture, and the
fifth case underwent Whipple’s operation; therefore,
no steroid was given in these 2 cases. Pancreatic
enlargement and biliary strictures can improve spon-
taneously in some AIP.8 Pancreatic enlargement and
narrowing of the MPD can improve with steroid
therapy in almost all patients, though some irregular-
ity of the MPD and side branches can remain.40 CBD
stricture can improve with varying degrees and biliary
drainage tube can be removed in almost all patients.40
Extrapancreatic lesions such as salivary gland and
lymph node enlargement, and retroperitoneal fibrosis
can improve with steroid therapy.41
Recurrence after steroid therapy ranged from 6%
to 31%.9,42 The reason for recurrence in our second
case was probably due to lower steroid dose owing to
the complication of esophageal Candidiasis. Zambomni
et al also reported a recurrence rate of 67% (2 of 3
cases) with steroid therapy.43 For those with recurrence,
high-dose steroid should be re-administered.40 Steroid
is effective and indicative, particularly in those with
CBD stricture or positive immunoserologic results.8
The following points can be used to differentiate
AIP from alcoholic chronic pancreatitis. AIP usually
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does not cause severe pain,3 the enlarged pancreas usu-
ally has no or only mild peripancreatic fat infiltration,
and phlegmonous changes, peripancreatic fluid and
pseudocysts are rare, whereas alcoholic chronic pan-
creatitis may have calcification and pancreaticoliths.44
ERP in AIP usually shows diffuse or segmental MPD
narrowing without much upstream dilatation of the
MPD or side branches.22 With steroid therapy, the nar-
rowing of the MPD will show a response in 2 weeks.44
In conclusion, AIP should be considered in the dif-
ferential diagnosis in distal CBD stricture and pancre-
atic head mass when the patient has: (1) diffuse or long
segmental enlargement of the pancreas without peri-
pancreatic fat infiltration, with multiple narrowing of
the MPD without much upstream dilatation, or nar-
rowing of the MPD not corresponding to the region
of CBD stricture; and (2) abnormal immunoserologic
tests.
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